These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33184050)
41. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622 [TBL] [Abstract][Full Text] [Related]
42. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502 [TBL] [Abstract][Full Text] [Related]
43. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769 [TBL] [Abstract][Full Text] [Related]
44. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597 [TBL] [Abstract][Full Text] [Related]
45. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial. Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM Front Immunol; 2022; 13():1023023. PubMed ID: 36330525 [TBL] [Abstract][Full Text] [Related]
46. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Noguchi M; Mine T; Yamada A; Obata Y; Yoshida K; Mizoguchi J; Harada M; Suekane S; Itoh K; Matsuoka K Oncol Res; 2007; 16(7):341-9. PubMed ID: 17518272 [TBL] [Abstract][Full Text] [Related]
47. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Kitano S; Kageyama S; Nagata Y; Miyahara Y; Hiasa A; Naota H; Okumura S; Imai H; Shiraishi T; Masuya M; Nishikawa M; Sunamoto J; Akiyoshi K; Kanematsu T; Scott AM; Murphy R; Hoffman EW; Old LJ; Shiku H Clin Cancer Res; 2006 Dec; 12(24):7397-405. PubMed ID: 17189412 [TBL] [Abstract][Full Text] [Related]
48. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352 [TBL] [Abstract][Full Text] [Related]
49. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569 [TBL] [Abstract][Full Text] [Related]
50. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639 [TBL] [Abstract][Full Text] [Related]
51. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518 [TBL] [Abstract][Full Text] [Related]
52. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
53. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612 [TBL] [Abstract][Full Text] [Related]
54. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205 [TBL] [Abstract][Full Text] [Related]
55. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172 [TBL] [Abstract][Full Text] [Related]
56. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020 [TBL] [Abstract][Full Text] [Related]
57. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells. Anastasopoulou EA; Voutsas IF; Papamichail M; Baxevanis CN; Perez SA Oncoimmunology; 2016 Jul; 5(7):e1178439. PubMed ID: 27622033 [TBL] [Abstract][Full Text] [Related]
58. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339 [TBL] [Abstract][Full Text] [Related]
59. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783 [TBL] [Abstract][Full Text] [Related]
60. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer. Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]